Kentucky Statutes 217.5405 – Limitations on impact KRS 217.5401 to 217.5408 may have on insurance coverage or health facility services — Coverage permitted — Approval of health facility for use
Current as of: 2024 | Check for updates
|
Other versions
(1) KRS § 217.5401 to KRS § 217.5408 shall not:
(a) Expand the coverage required of an insurer;
(b) Affect the requirements for insurance coverage of routine patient costs for patients involved in approved cancer clinical trials;
(c) Require a health plan, third-party administrator, or governmental agency to pay costs associated with the use, care, or treatment of an eligible patient with an investigational drug, biological product, or device; or
(d) Require a hospital or health facility to provide new or additional services.
(2) A health plan, third-party administrator, or governmental agency may provide coverage for the cost of an investigational drug, biological product, or device or the cost of services related to the use of an investigational drug, biological product, or device under KRS § 217.5401 to KRS § 217.5408.
(3) A hospital or health facility may approve the use of an investigational drug, biological product, or device in the hospital or health facility.
Effective: June 29, 2017
History: Created 2017 Ky. Acts ch. 65, sec. 5, effective June 29, 2017.
Formerly codified as KRS § 217.5409.
(a) Expand the coverage required of an insurer;
Terms Used In Kentucky Statutes 217.5405
- Device: means any instrument or contrivance other than a firearm which is intended for trapping, destroying, repelling, or mitigating any pest or any other form of plant or animal life other than man and other bacteria, virus, or other microorganisms on or in living man or other living animals. See Kentucky Statutes 217.544
- Treatment: when used in a criminal justice context, means targeted interventions
that focus on criminal risk factors in order to reduce the likelihood of criminal behavior. See Kentucky Statutes 446.010
(b) Affect the requirements for insurance coverage of routine patient costs for patients involved in approved cancer clinical trials;
(c) Require a health plan, third-party administrator, or governmental agency to pay costs associated with the use, care, or treatment of an eligible patient with an investigational drug, biological product, or device; or
(d) Require a hospital or health facility to provide new or additional services.
(2) A health plan, third-party administrator, or governmental agency may provide coverage for the cost of an investigational drug, biological product, or device or the cost of services related to the use of an investigational drug, biological product, or device under KRS § 217.5401 to KRS § 217.5408.
(3) A hospital or health facility may approve the use of an investigational drug, biological product, or device in the hospital or health facility.
Effective: June 29, 2017
History: Created 2017 Ky. Acts ch. 65, sec. 5, effective June 29, 2017.
Formerly codified as KRS § 217.5409.